GSK starts build of its largest Indian tablet manufacturing pharmaceutical factory in Vemgal, Karnataka

GSK starts build of its largest Indian tablet manufacturing pharmaceutical factory in Vemgal, Karnataka

Hon'ble Chief Minister of Karnataka, Shri Siddaramaiah lays the foundation stone of the new pharmaceutical factory 

8 September 2015, Mumbai, India and London UK--Work on GSK India's new Rs.1000 (£100m) crore pharmaceutical factory started today as the company restated its commitment to ensuring access to its medicines for the people of India.

When fully operational in 2017, the factory will make more than 8 billion tablets and 1 billion capsules a year in the areas of gastroenterology and anti-inflammatory medicines for the Indian market. The facility will be built on a 50-acre site in Vemgal, Karnataka. The factory is expected to employ in the region of 300 people once in operation.

The new state of the art manufacturing facility is part of GSK's continued commitment to India, ensuring increased access to GSK medicines for people in the country. The factory will be built in partnership with international and local design and construction companies. The facility will also include a warehouse, site infrastructure, employee welfare centre and utilities to support the manufacturing and packing of the medicines.

Today, Karnataka Chief Minister Shri Siddaramaiah laid the foundation stone witnessed by Lord Francis Maude, the UK's Trade & Industry Minister. Other dignitaries also present on the occasion were Shri R. V. Deshpande, Hon'ble Minister for Large & Medium Scale Industries & Tourism, Shri U. T. Khader, Hon'ble Minister for Health & Family Welfare, Shri K. H. Muniyappa, Former Union Minister & Hon'ble Member of Parliament, Shri R. Varthur Prakash, Hon'ble Member of Legislative Assembly, Mrs. K. Ratna Prabha (IAS), Hon'ble Addl. Chief Secretary – Commerce & Industries Dept., Ian Felton, Hon'ble British Deputy High Commissioner and Annaswamy Vaidheesh, Managing Director, GlaxoSmithKline Pharmaceuticals, India.

Speaking on this occasion, Shri Siddaramaiah, Hon'ble Chief Minister of Karnataka said, "GlaxoSmithKline Pharmaceuticals Limited's state-of-the-art plant in Kolar District is yet another major investment by a multinational company in Karnataka which hopefully, will prompt other companies to come and invest in the State."

Annaswamy Vaidheesh, Managing Director, GlaxoSmithKline Pharmaceuticals, India said, "GSK has been at the forefront of serving the healthcare needs of India for more than 90 years. We fully support the Government in their efforts to increase access to affordable medicines to improve healthcare and we are very excited to begin work on what will become our largest manufacturing facility in India. With this new facility, we aim to further strengthen our commitment to helping the patients in India to improve their health and wellbeing."

GSK – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

GSK enquiries:

India Media enquiries: Ransom D'Souza +91 98202 34999 (Mumbai)

UK Media enquiries: Simon Steel +44 (0) 20 8047 5502 (London)

Anna Carruth +44 (0) 20 8047 5502 (London)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2013.

 

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.